GLPwatch
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Diabetes Res Clin Pract · 2010
Last updated 2026-05-28A 54-year-old woman with type 2 diabetes, who was not well-controlled on three medications, lost 33 kg after adding Exenatide. She maintained normal blood sugar levels for at least 7 months after stopping all diabetes medications, including Exenatide.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2010 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.02 |
| NIH percentile | 4 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
A 54-year-old obese woman with poorly controlled type 2 diabetes was put on the maximum allowed doses of Metformin, Glimepiride and Rosiglitazone. When Exenatide was added, she lost 33 kg. She remained euglycemic for at least 7 months after the sequential discontinuation of Exenatide and the other oral agents.
Verbatim abstract via PubMed 21030101 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.